

**PROVIDER NOTIFICATION OF RETAIL DRUG
POLICY CRITERIA CHANGE**

Drug Impacted	CRITERIA CHANGE	EFFECTIVE DATE	Formulary
Pomalyst	For multiple myeloma (MM): added requirement for relapsed or progressive disease per NCCN, added requirement for steroid intolerant if used as a single agent per NCCN, added regimen with daratumumab/hyaluronidase and dexamethasone per Darzalex Faspro label and NCCN. Added coverage for MM with CNS disease per NCCN.	05/02/2026	Standard, Metallic and Essential
Revlimid, lenalidomide	For hepatosplenic T-cell lymphoma, added requirement for refractory disease after two regimens per NCCN. For primary CNS lymphoma, removed criteria for prior therapy per NCCN. For CLL/SLL, added criteria for prior therapy per NCCN. For nodal MZL, removed requirement for use as subsequent therapy per NCCN B-cell lymphoma GL. For classic Hodgkin lymphoma, added clinical setting and not a candidate for stem cell rescue per NCCN. For POEMS, removed regimens per NCCN. Added coverage for MIDD and MGRS per NCCN. For MDS/MPN overlap neoplasms, added requirements for SF3B1 mutation and thrombocytosis per NCCN. Added coverage for Kaposi sarcoma associated herpesvirus -Associated Inflammatory Cytokine Syndrome per NCCN. Added coverage for relapsed or refractory mycosis fungoides or sezary syndrome per NCCN.	05/02/2026	Standard, Metallic and Essential
Thalomid	For Kaposi sarcoma, added regimens and clinical settings per NCCN. For chronic graft versus host disease, added requirement for refractory disease per AHFS DI. For aphthous stomatitis, added requirement for severe disease and removed requirement for immunocompromised members per AHFS DI.	05/02/2026	Standard, Metallic and Essential
Zirabev (bevacizumab biosimilar)	Updated appendiceal adenocarcinoma to appendiceal neoplasms and appendiceal cancers to align with NCCN. Removed coverage for unresectable ampullary adenocarcinoma, per NCCN. Updated verbiage from high grade glioma to H3-mutated high-grade glioma, High-grade astrocytoma with piloid features, Pleomorphic xanthoastrocytoma, per NCCN. Updated uterine neoplasms/endometrial carcinoma to endometrial carcinoma and removed coverage for progressive	05/02/2026	Essential

	disease and added coverage for stage III-IV disease, per NCCN. Added coverage for induction treatment of mesothelioma, per NCCN. Removed first-line requirement for treatment of hepatocellular carcinoma and removed coverage for adjuvant treatment of hepatocellular carcinoma, per NCCN. Updated continuation of therapy language for non-small cell lung cancer and CNS cancers, per NCCN.		
Braftovi	Aligned coverage for neoadjuvant treatment of cutaneous melanoma to stage III disease, per NCCN. Expanded coverage for advanced colorectal cancer when given in combination with FOLFOX and Erbitux or Vectibix. Expanded coverage for appendiceal cancer under its own coverage criteria, per NCCN.	05/02/2026	Standard, Metallic, and Essential
Mektovi	For neoadjuvant treatment of melanoma, added requirement of stage III disease per NCCN. For Langerhans cell histiocytosis, added criteria if cobimetinib or trametinib are not tolerated per NCCN.	05/02/2026	Standard, Metallic, and Essential
Tafinlar	For melanoma, added requirement for subsequent therapy when used in combination with Mekinist and Keytruda and added stage III for neoadjuvant therapy per NCCN. Added coverage for ampullary adenocarcinoma per NCCN. For pancreatic adenocarcinoma, added requirement for subsequent treatment for recurrent or metastatic disease. Updated gastric cancer for palliative therapy per NCCN. Added previously treated hairy cell leukemia with incomplete hematologic recovery, per NCCN.	05/02/2026	Standard, Metallic and Essential
Mekinist	For melanoma, added requirement for subsequent therapy when used in combination with Tafinlar and Keytruda and added stage III for neoadjuvant therapy per NCCN. Added coverage for ampullary adenocarcinoma per NCCN. For pancreatic adenocarcinoma, added requirement for subsequent treatment for recurrent or metastatic disease. Updated gastric cancer for palliative therapy per NCCN. Added previously treated hairy cell leukemia with incomplete hematologic recovery, per NCCN. Added coverage for epithelioid hemangioendothelioma per NCCN.	05/02/2026	Standard, Metallic and Essential
bortezomib	For POEMS syndrome, removed requirement for use in combination with dexamethasone. Added coverage for plasma cell-related Monoclonal	04/18/2026	Essential

	Immunoglobulin Deposition Disease (MIDD) and plasma cell-related Monoclonal Gammopathy of Renal Significance (MGRS) per NCCN.		
Ninlaro	For multiple myeloma when used in combination with lenalidomide and dexamethasone, removed requirement of at least one prior therapy per NCCN. Added coverage for POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, plasma cell-related monoclonal immunoglobulin deposition disease (MIDD), and plasma cell-related monoclonal gammopathy of renal significance (MGRS) per NCCN.	04/18/2026	Standard and Essential
Erivedge	Included use in combination with radiation therapy for the treatment of basal cell carcinoma, per NCCN.	04/18/2026	Standard, Metallic and Essential
buprenorphine	Increased initial quantity limit and post limit quantity for Buprenorphine SL 8 mg tablets to 120 tablets per month.	04/18/2026	Standard, Metallic, Complete, and Essential
Dificid	Removed generic fidaxomicin from target drug box (Brand DIFICID remains targeted). Added generic fidaxomicin to pre-requisite step therapy. Updated document title.	04/18/2026	Complete and Essential
ADHD Agents	Removed Evekeo ODT from criteria (product no longer available).	04/18/2026	Standard, Metallic, Complete and Essential